Browse News

Found 42 articles

• Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference

  1/10/2021

  Sorrento Therapeutics, Inc., announced that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference

• Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™ Rapid Detection Test of SARS-CoV-2 Viral Antigen

  12/30/2020

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that a Marketing Authorization Application has been submitted by its agents in Mexico to Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the health regulatory authority for Mexico, for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients,

• Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen

  12/22/2020

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that an Emergency Use Authorization (EUA) Application has been submitted to the US Food and Drug Administration for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients.

• Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients

  12/9/2020

  FDA has granted clearance for the commencement of Phase 1 clinical trials of STI-2020 (COVI-AMG TM ) in healthy volunteers and COVID-19 patients with mild symptoms. STI-2020, a monoclonal antibody, has been engineered for ultra-high potency, which potentially translates to a smaller IV volume required to administer an effective dose. In preclinical studies, STI-2020 demonstrated strong or stronger affinities to multiple antibody drug-resistant SARS-CoV-2 variants. Outpatient trials are expect

• Sorrento Receives Licensure From the State of California for Clinical Testing Laboratory (CLIA) Allowing for Clinical Sample Testing

  12/8/2020

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has received CLIA Licensure from the State of California that permits testing of clinical samples.

• DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies

  11/27/2020

  Initial funding of up to $34 million for the project “Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus” (HR0011-21-9-0015) to support the development of an STI-2020-encoded Gene MAbTM through Phase 2 clinical studies.

• Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2

  11/11/2020

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intranasal (IN) COVI-DROPS (STI-2099) to study the safety and pharmacokinetics in both healthy volunteers and patients with mild COVID-19.

• Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2

  11/9/2020

  IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers. These initial trials are expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use Authorization). Animal model data (golden Syrian hamsters infected with SARS-CoV-2) demonstrated a highly effective neutralizing profile.

• Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutralizing Antibody Prevented COVID-19 Disease Progression in Infected Hamsters Following SARS-CoV-2 Infection

  10/29/2020

  In an IND-enabling study, intranasal COVI-AMG nAb (STI-2099 or COVI-DROPSTM) very early on decreased COVID-19 disease severity and shortened the duration of the disease in infected hamsters

• Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients

  10/14/2020

  Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S. Studies are complementary and address both dose duration and disease stage Rapid enrollment expected for both geographies SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib

• Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies

  10/12/2020

  Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem Cells, Inc. (PSC) to acquire global rights to its adipose derived mesenchymal stem cells (MSCs) for patients suffering from acute respiratory distress syndrome (ARDS) associated with COVID-19, which have been cleared for a Phase 1 clinical trial by the FDA. The study is a single arm, non-randomized P

• Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released

  10/9/2020

  Sorrento Therapeutics, Inc. released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020.

• Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies

  10/7/2020

  In preclinical studies, Salicyn-30, a small molecule, demonstrated potent in-vitro viral load reduction of 3-4 log in SARS-CoV-2 infection model in normal healthy VERO E6 cells. Salicyn-30 displays a novel mechanism of inhibition of SARS-CoV-2, with potential additive benefits when used in a multi-modal therapy approach. Salicyn-30 can potentially be administered orally alone and will be tested in combination with Sorrento’s potent STI-1499 and affinity matured STI-2020 neutralizing antibo

• Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020

  10/7/2020

  SP-102 could potentially be the first FDA approved epidural steroid product for the treatment of sciatica with the potential to replace the current 10 to 11 million off-label epidural steroid injections administered each year in the U.S.

• Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline

  10/4/2020

  Sorrento Therapeutics, Inc. announced it will host a R&D Day conference call and simultaneous webcast on October 13th, 2020 focusing on its comprehensive multi-modal approach to COVID-19.

• SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19

  9/30/2020

  Sorrento to initiate testing with a selection of its agents in combination with ViralClear’s anti-viral compound for possible synergistic anti-viral effect against SARS-CoV-2 in the preclinical model of Golden Syrian hamster. ViralClear to contribute its oral antiviral merimepodib (IMPDH inhibitor) which is currently in a Phase 2 trial in combination with remdesivir to treat COVID-19. Sorrento to initially make available STI-1400 neutraliz

• Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19

  9/30/2020

  ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced the companies are exploring the synergistic potential of small molecules and antibodies combination therapies against COVID-19.

• Sorrento Releases Preclinical Data for STI-1499 (COVI-Guard™) and STI-2020 (COVI-AMG™), Potent Neutralizing Antibodies Against SARS-CoV-2

  9/29/2020

  In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus.

• Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain

  9/28/2020

  Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) with completed Day 84 effectiveness data (end-point analysis) for all patients and completed six-month follow-ups in all doses for all patients enrolled, with no negative safety signal as of September 2020.

• Sorrento Therapeutics Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) Epidural in Cancer Patients with Reported Intractable Pain

  9/22/2020

  Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg). No dose limiting toxicities were reported. A majority of patients reported meaningful pain reduction of 30% or more from baseline. Sorrento expects to submit to the FDA a request to proceed with a Phase 3 clinical trial in this orphan indication imminently. SAN DIEGO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced the public release of the results of it